drugset / Trial / NCT01260506

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.

Timeline

Start
2010-12
Primary completion
2015-07-23
Completion
2018-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject VB-111 Other / unclassified
Background Bevacizumab Monoclonal antibody

Indications